Trans-arterial radio-embolization (TARE) with yttrium-90 represents one of the most efficacious approaches for the treatment of selected patients with advanced hepatocellular cancer (HCC) (1). Recent studies have confirmed the superiority of TARE when compared with other intraarterial treatments (2,3). A randomized phase II study comparing TARE and trans-arterial chemo-embolization (TACE) in HCC patients meeting Barcelona Clinic Liver Cancer stages A-B showed a longer median timeto- progression (>26 vs. 6.8 months; P value =0.001), and a better tumor control in post-TARE cases (2). Another study similarly compared TARE and TACE patients homogeneously selected using a propensity score matching: also in this case, TARE presented higher overall complete response rates (84% vs. 58%; P value <0.001), and longer median progression-free survivals (564 vs. 271 days; P value =0.002) (3).
Radioembolization in the setting of liver transplantation. Great expectations or hard times? / Lai, Quirino; Mennini, Gianluca. - In: HEPATOBILIARY SURGERY AND NUTRITION. - ISSN 2304-3881. - STAMPA. - 7:1(2018), pp. 58-60. [10.21037/hbsn.2017.12.10]
Radioembolization in the setting of liver transplantation. Great expectations or hard times?
Lai, Quirino;Mennini, Gianluca
2018
Abstract
Trans-arterial radio-embolization (TARE) with yttrium-90 represents one of the most efficacious approaches for the treatment of selected patients with advanced hepatocellular cancer (HCC) (1). Recent studies have confirmed the superiority of TARE when compared with other intraarterial treatments (2,3). A randomized phase II study comparing TARE and trans-arterial chemo-embolization (TACE) in HCC patients meeting Barcelona Clinic Liver Cancer stages A-B showed a longer median timeto- progression (>26 vs. 6.8 months; P value =0.001), and a better tumor control in post-TARE cases (2). Another study similarly compared TARE and TACE patients homogeneously selected using a propensity score matching: also in this case, TARE presented higher overall complete response rates (84% vs. 58%; P value <0.001), and longer median progression-free survivals (564 vs. 271 days; P value =0.002) (3).File | Dimensione | Formato | |
---|---|---|---|
Lai_Radioembolization_2018.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
110.03 kB
Formato
Adobe PDF
|
110.03 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.